HomeEverythingEducation
Equities & FundsCrypto & Digital AssetsAI & TechnologyBusiness & CorporateUS Politics & PolicyGeopolitics & Global RiskMacro, Rates & FXCommodities & EnergyEuropean Politics & MarketsAsia-PacificReal Estate & Property
Story archiveAll categories
← All Stories

Aphranel Filler Receives EU MDR Certification

Created at 1 Jun · 3:55 AM2 sources↑ Market-relevant2 events
IN SHORT

Moyom Biotechnology announced that its Aphranel MagiCCrystal CaHA Filler has received EU MDR certification on May 18, 2026. This certification allows the product to be marketed in the European Union, signifying compliance with high standards for quality and patient safety.

✉Newsletter

PiQ Daily

Pick your topics. Get only what matters, on your cadence.

Key Numbers

May 18, 2026EU MDR certification date

Who's Involved

Moyom Biotechnology
announced EU MDR certification for Aphranel MagiCCrystal CaHA Filler

↳ Why This Matters

The European Union's Medical Device Regulation (EU MDR) is a stringent set of rules governing the safety and performance of medical devices sold within the EU. Obtaining this certification is a significant step for medical aesthetic products, indicating compliance with high standards for quality and patient safety. This allows Moyom Biotechnology to expand its market reach into the European Union.

Key facts

  • Aphranel MagiCCrystal CaHA Filler received EU MDR certification on May 18, 2026.
  • The certification allows the product to be marketed in the European Union.
  • Moyom Biotechnology is the manufacturer of the filler.

The European Union's Medical Device Regulation (EU MDR) is a stringent set of rules governing the safety and performance of medical devices sold within the EU. Obtaining this certification is a significant step for medical aesthetic products, indicating compliance with high standards for quality and patient safety. This allows Moyom Biotechnology to expand its market reach into the European Union.

Frequently asked questions

Aphranel MagiCCrystal CaHA Filler is a regenerative aesthetic product manufactured by Moyom Biotechnology.

EU MDR certification is a regulatory approval required for medical devices to be marketed and sold within the European Union, ensuring they meet high standards for safety and performance.

This certification allows Moyom Biotechnology to legally market and sell its Aphranel MagiCCrystal CaHA Filler product within the European Union.

What Happens Next

01Aphranel MagiCCrystal CaHA Filler will be available for marketing in the European Union.

Get the newsletter.

Pick the topics you actually care about. We'll email when there's news worth your time, on the cadence you choose. Cancel any time from your account.

Cadence

How It Developed

1 Jun · 3:50 AM
Aphranel® MagiCCrystal CaHA Filler has received EU MDR certification as a premium regenerative injectable on May 18, 2026.
PRN | All News Releases via PiQSuite

Sources

T1
Aphranel® MagiCCrystal CaHA Filler erhält die EU MDR-Zertifizierung als hochwertiges regeneratives Injektionsmittelm.piqsuite.com
T1
Aphranel® MagiCCrystal CaHA Filler obtient la certification MDR de l'UE en tant qu'injectable régénérateur de première qualitém.piqsuite.com

Related Stories

Europe's most pet-friendly countries for employees revealed
9 Jul · 8:10 AM
Paramount Delays Warner Bros. Deal Amid Oregon Antitrust Probe
9 Jul · 1:44 AM
Airbus deliveries rise 15% to 351 in first half
8 Jul · 3:55 PM
Natura's Q2 Revenue Declines 9-10% Amid Restructuring
8 Jul · 12:04 PM
37 killed in China shoe factory fire; unlicensed operation cited
9 Jul · 9:58 AM